|
1
|
Mato A, Svoboda J, Luning Prak E, Schuster S, Tsao P, Dorsey C, Sarmasti L, Becker P, Brander D, Nasta S, Landsburg D, King C, Morrigan B, Elwell J, Kennard K, Roeker L, Zelenetz A, Purdom M, Paskalis D, Sportelli P, Miskin H, Weiss M, Shadman M. PHASE I/II STUDY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB (TG-1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION. Hematol Oncol 2019. [DOI: 10.1002/hon.79_2629] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A.R. Mato
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - J. Svoboda
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - E.T. Luning Prak
- Department of Pathology and Laboratory Medicine; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - S.J. Schuster
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - P.Y. Tsao
- Department of Pathology and Laboratory Medicine; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - C. Dorsey
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - L.M. Sarmasti
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - P.S. Becker
- Department of Hematology; Fred Hutchinson Cancer Research Center; Seattle WA United States
| | - D.M. Brander
- Division of Hematologic Malignancies; Duke University Medical Center; Durham NC United States
| | - S. Nasta
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - D.J. Landsburg
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - C.M. King
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - B. Morrigan
- Department of Hematology; Fred Hutchinson Cancer Research Center; Seattle WA United States
| | - J. Elwell
- Department of Hematology; Fred Hutchinson Cancer Research Center; Seattle WA United States
| | - K. Kennard
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - L. Roeker
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - A.D. Zelenetz
- Lymphoma Service; Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - M. Purdom
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - D. Paskalis
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - P. Sportelli
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - H.P. Miskin
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - M.S. Weiss
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - M. Shadman
- Department of Hematology; Fred Hutchinson Cancer Research Center; Seattle WA United States
| |
Collapse
|
|
2
|
Mato A, Schuster S, Lamanna N, Pagel J, Flinn I, Barrientos J, Reeves J, Cheson B, Barr P, Kambhampati S, Lansigan F, Pu J, Skarbnik A, Fonseca G, Dorsey C, LaRatta N, Weissbrot H, Svoboda J, Luning Prak E, Tsao P, Sitlinger A, Paskalis D, Sportelli P, Miskin H, Weiss M, Brander D. A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY. Hematol Oncol 2019. [DOI: 10.1002/hon.56_2629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A.R. Mato
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - S.J. Schuster
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - N. Lamanna
- Columbia University Medical Center; New York-Presbyterian; New York United States
| | - J.M. Pagel
- Department of Hematology; Swedish Cancer Institute; Seattle WA United States
| | - I.W. Flinn
- TN Oncology; Sarah Cannon Research Institute; Nashville TN United States
| | - J. Barrientos
- CLL Research and Treatment Program; Northwell Health; New Hyde Park NY United States
| | - J.A. Reeves
- Florida Cancer Specialists; Sarah Cannon Research Institute; Fort Myers FL United States
| | - B.D. Cheson
- Lombardi Comprehensive Cancer Center; Georgetown University Hospital; Washington DC United States
| | - P.M. Barr
- Wilmot Cancer Institute; University of Rochester; Rochester NY United States
| | - S. Kambhampati
- Research Medical Center; Sarah Cannon Research Institute; Kansas City MO United States
| | - F. Lansigan
- Department of Hematology; Dartmouth-Hitchcock Medical Center; Lebanon NH United States
| | - J.J. Pu
- Department of Hematology; Penn State Health; Hershey PA United States
| | - A. Skarbnik
- Department of Hematology; John Theurer Cancer Center; Hackensack NJ United States
| | - G. Fonseca
- Florida Cancer Specialists North; Sarah Cannon Research Institute; St. Petersburg FL United States
| | - C. Dorsey
- CLL Program; Leukemia Service, Memorial Sloan-Kettering Cancer Center; New York NY United States
| | - N.M. LaRatta
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - H. Weissbrot
- Columbia University Medical Center; New York-Presbyterian; New York United States
| | - J. Svoboda
- Lymphoma Department; University of Pennsylvania, Abramson Cancer Center; Philadelphia PA United States
| | - E.T. Luning Prak
- Clinical Immunology Laboratory; University of Pennsylvania; Philadelphia PA United States
| | - P. Tsao
- Clinical Immunology Laboratory; University of Pennsylvania; Philadelphia PA United States
| | - A. Sitlinger
- Department of Hematology; Duke University Medical Center; Durham NC United States
| | - D. Paskalis
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - P. Sportelli
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - H.P. Miskin
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - M.S. Weiss
- Clinical Development; TG Therapeutics, Inc.; New York NY United States
| | - D.M. Brander
- Department of Hematology; Duke University Medical Center; Durham NC United States
| |
Collapse
|